







# ACTIVE CEPI-FUNDED VACCINE CANDIDATE PORTFOLIO BY PHASE

	Preclinical	Phase I	Phase II	Phase IIb/III & III	Registration
Lassa	University of Oxford/Janssen	Emergent IAVI			
MERS-CoV		University of Oxford/Janssen IDT			
Nipah	University of Oxford/Janssen	Auro Vaccines PHV			
Rift Valley Fever	Colorado State U.	Wageningen U.			
Chikungunya				IVI/Bharat	Valneva
SARS-CoV-2 (1)		Gritstone			SK Bioscience Biological E Moderna Clover Novavax AZ/Oxford University of Hong Kong
Broadly protective coronavirus	MigVax VIDO Bionet CPI/CalTech Bharat/U Syd/ExcellGene NEC SK Bioscience Intravacc Panacea/THSTI	VBI			




● = SARS-CoV-2  
● = Beta-coronavirus

(1) CEPI has also funded booster studies of SARS-CoV-2 vaccines developed by Medigen and Vaxxinity

PATHOGEN	DEVELOPER	PHASE	PLATFORM	CEPI FUNDING
 Lassa	University of Oxford/ Janssen	Preclinical	Viral Vector	up to US \$19.0 million (2)
	IAVI	Phase I	Viral Vector	up to US \$64.4 million
	Emergent	Phase I	Viral vector	up to US \$36.0 million
 MERS-CoV	University of Oxford/ Janssen	Phase I	Viral vector	up to US \$19.0 million (2)
	IDT	Phase I	Viral vector	up to US \$36.0 million
 Nipah	University of Oxford/ Janssen	Preclinical	Viral Vector	up to US \$19.0 million (2)
	Auro Vaccines	Phase I	Protein based	up to US \$25.0 million
	PHV	Phase I	Viral vector	up to US \$43.6 million
 RVF	Colorado State University	Preclinical	Live attenuated	up to US \$9.5 million
	Wageningen University	Phase I	Live attenuated	up to US \$12.5 million
 Chikungunya	IVI/Bharat	Phase IIb/III	Inactivated	up to US \$14.1 million
	Valneva	Registration	Live attenuated	up to US \$23.4 million
 SARS-CoV-2	Gritstone	Phase I	RNA	up to US \$25.6 million
	SK Bioscience	Registration	Protein based	up to US \$210.0 million (3)
	Biological E	Registration	Protein based	up to US \$14.0 million
	Moderna	Registration	Protein based	up to US \$1.0 million

(2) Funding for Lassa, MERS and Nipah

(3) Funding for Lassa and MERS

PATHOGEN	DEVELOPER	PHASE	PLATFORM	CEPI FUNDING
 SARS-CoV-2	Clover	Registration	Protein based	up to US \$397.4 million
	AZ/University of Oxford	Registration	Viral vector	up to US \$384.0 million
	Novavax	Registration	Protein based	up to US \$399.0 million
 Broadly protective SARS-CoV-2	MigVax	Preclinical	Protein based	up to US \$4.3 million
	BioNet	Preclinical	RNA	up to US \$16.9 million
	VIDO	Preclinical	Protein based	up to US \$5.0 million
	Bharat/ U Sydney/ ExcellGene	Preclinical	Protein based	up to US \$19.9 million
 Broadly protective Beta-coronavirus	CPI/Caltech	Preclinical	Protein based	up to US \$30.0 million
	NEC	Preclinical	RNA	up to US \$4.8 million
	SK Bioscience	Preclinical	Protein based	up to US \$50.0 million
	Panacea/THSTI	Preclinical	Protein based	up to US \$12.5 million
	Intravacc	Preclinical	Protein based	up to US \$4.8 million
	VBI Vaccines	Phase I	Protein based	up to US \$33.0 million